The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; MSD; Pierre Fabre
Consulting or Advisory Role - Delcath Systems; Immunocore; MSD
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); MSD (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Consulting or Advisory Role - Castle Biosciences; Genzyme; Immunocore; InxMed; Iovance Biotherapeutics; Merck; OncoSec; Pierre Fabre; PureTech; Regeneron; Sorrento Therapeutics; TriSalus Life Sciences
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
 
Marlana Orloff
Consulting or Advisory Role - Immunocore
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Richard D. Carvajal
No Relationships to Disclose
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - Bristol-Myers Squibb; Immunocore; Polaris; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Joseph J. Sacco
No Relationships to Disclose
 
Max Schlaak
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme; Immunocore; Kyowa Kirin; MSD; Novartis; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Novartis; Pierre Fabre; Sun Pharma
 
Claire Watkins
Consulting or Advisory Role - Actinium Pharmaceuticals; Ascelia; Astellas Pharma; AstraZeneca; Carrick Therapeutics; Celgene/Bristol-Myers Squibb; Evgen; Humanigen; Immunocore; Nobelpharma; Novo Nordisk; Roche
 
Shaad Essa Abdullah
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
Patents, Royalties, Other Intellectual Property - AU2019270277A1 - Treatment of Cancer; WO2020225552A1 - Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
 
Howard Goodall
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; Iovance Biotherapeutics; LaRoche Posay; Merck; Novartis; Sanofi; Sun Pharma
Research Funding - Merck; Takara Bio
Expert Testimony - Merck